Cancers 2011, 3(1), 79-90; doi:10.3390/cancers3010079

Screening Technologies for Target Identification in Pancreatic Cancer

* email, , email and
Received: 23 November 2010; in revised form: 21 December 2010 / Accepted: 23 December 2010 / Published: 29 December 2010
(This article belongs to the Special Issue Pancreatic Cancer)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Pancreatic cancer exhibits an extraordinarily high level of resistance to almost any kind of systemic therapy evaluated in clinical trials so far. Therefore, the identification of novel therapeutic targets is urgently required. High-throughput screens have emerged as an important tool to identify putative targets for diagnosis and therapy in an unbiased manner. More than a decade ago, microarray technology was introduced to identify differentially expressed genes in pancreatic cancer as compared to normal pancreas, chronic pancreatitis and other cancer types located in close proximity to the pancreas. In addition, proteomic screens have facilitated the identification of differentially secreted proteins in body fluids of pancreatic cancer patients, serving as possible biomarkers. Recently, RNA interference-based loss-of-function screens have been used to identify functionally relevant genes, whose knock-down has impact on pancreatic cancer cell viability, thereby representing potential new targets for therapeutic intervention. This review summarizes recent results of transcriptional, proteomic and functional screens in pancreatic cancer and discusses potentials and limitations of the respective technologies as well as their impact on future therapeutic developments.
Keywords: pancreatic cancer; high-throughput screen; microarray; RNA interference; loss-of-function screen
PDF Full-text Download PDF Full-Text [306 KB, uploaded 29 December 2010 12:02 CET]

Export to BibTeX |

MDPI and ACS Style

Michl, P.; Ripka, S.; Gress, T.; Buchholz, M. Screening Technologies for Target Identification in Pancreatic Cancer. Cancers 2011, 3, 79-90.

AMA Style

Michl P, Ripka S, Gress T, Buchholz M. Screening Technologies for Target Identification in Pancreatic Cancer. Cancers. 2011; 3(1):79-90.

Chicago/Turabian Style

Michl, Patrick; Ripka, Stefanie; Gress, Thomas; Buchholz, Malte. 2011. "Screening Technologies for Target Identification in Pancreatic Cancer." Cancers 3, no. 1: 79-90.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert